XML 23 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Total
Series B Convertible Preferred Stock
Common Stock
Preferred Stock
Preferred Stock
Series B Convertible Preferred Stock
Additional Paid-in Capital
Additional Paid-in Capital
Series B Convertible Preferred Stock
Accumulated Other Comprehensive (Loss) Income
Accumulated Deficit
Beginning Balances at Dec. 31, 2018 $ 63,065   $ 63   $ 1,131,241   $ (2,015) $ (1,066,224)
Beginning Balances (in shares) at Dec. 31, 2018     62,862,000          
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net (2)   $ 1     (1)      
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net (in shares)     975,000            
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)     19,912,000   5,000        
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement 60,113 $ 12,061 $ 20     60,093 $ 12,061    
Issuance of common stock under Employee Stock Purchase Plan 565         565      
Issuance of common stock under Employee Stock Purchase Plan (in shares)     122,000            
Stock compensation expense 25,456         25,456      
Total other comprehensive loss (372)             (372)
Net income (loss) (152,600)               (152,600)
Ending Balances at Dec. 31, 2019 8,290   $ 84   1,229,417   (2,387) (1,218,824)
Ending Balances (in shares) at Dec. 31, 2019     83,871,000 5,000          
Conversion of Preferred Stock 1   $ 1            
Stock Issued During Period, Shares, Conversion of Convertible Securities     700,000            
Stock Redeemed During Period, Shares, Conversion of Convertible Securities (in shares)       (1,000)          
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net 289   $ 1     288      
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net (in shares)     1,209,000            
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)     24,215,000            
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement 108,537   $ 24     108,513      
Issuance of common stock under Employee Stock Purchase Plan 672         672      
Issuance of common stock under Employee Stock Purchase Plan (in shares)     195,000            
Stock compensation expense 13,484         13,484      
Total other comprehensive loss 2,660             2,660
Net income (loss) (75,240)               (75,240)
Ending Balances at Dec. 31, 2020 58,693   $ 110   1,352,374   273 (1,294,064)
Ending Balances (in shares) at Dec. 31, 2020     110,190,000 4,000          
Conversion of Preferred Stock     $ 4     (4)      
Stock Issued During Period, Shares, Conversion of Convertible Securities     4,140,000            
Stock Redeemed During Period, Shares, Conversion of Convertible Securities (in shares)       4,000          
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net 6,577   $ 2     6,575      
Issuance (withholding) of common stock upon exercise of stock options and restricted stock awards, net (in shares)     1,560,000            
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement (Shares)     2,879,000            
Issuance of common stock, net of issuance costs, in conjunction with an underwritten public offering and an At Market Sales Agreement 28,156   $ 3     28,153      
Issuance of common stock under Employee Stock Purchase Plan 841         841      
Issuance of common stock under Employee Stock Purchase Plan (in shares)     217,000            
Issuance of common stock upon exercise of warrants (Shares)     3,959,000            
Issuance of common stock upon exercise of warrants 59,888   $ 4     59,884      
Issuance of capped call options (see Note 10) (27,240)         (27,240)      
Stock compensation expense 21,285         21,285      
Total other comprehensive loss (2,539)             (2,539)  
Net income (loss) 76,713               76,713
Ending Balances at Dec. 31, 2021 $ 222,374   $ 123   $ 1,441,868   $ (2,266) $ (1,217,351)
Ending Balances (in shares) at Dec. 31, 2021     122,945,000